| The multifaceted circulating endothelial cell in cancer: towards marker and target identification F Bertolini, Y Shaked, P Mancuso, RS Kerbel Nature Reviews Cancer 6 (11), 835-845, 2006 | 737 | 2006 |
| Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Y Shaked, A Ciarrocchi, M Franco, CR Lee, S Man, AM Cheung, ... Science 313 (5794), 1785-1787, 2006 | 687 | 2006 |
| Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells F Bertolini, S Paul, P Mancuso, S Monestiroli, A Gobbi, Y Shaked, ... Cancer research 63 (15), 4342-4346, 2003 | 629 | 2003 |
| Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents Y Shaked, E Henke, JML Roodhart, P Mancuso, MHG Langenberg, ... Cancer cell 14 (3), 263-273, 2008 | 539 | 2008 |
| Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors C Folkins, S Man, P Xu, Y Shaked, DJ Hicklin, RS Kerbel Cancer research 67 (8), 3560-3564, 2007 | 488 | 2007 |
| Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis Y Shaked, F Bertolini, S Man, MS Rogers, D Cervi, T Foutz, K Rawn, ... Cancer cell 7 (1), 101-111, 2005 | 468 | 2005 |
| Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1 C Folkins, Y Shaked, S Man, T Tang, CR Lee, Z Zhu, RM Hoffman, ... Cancer research 69 (18), 7243-7251, 2009 | 430 | 2009 |
| Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia M Bosch-Marce, H Okuyama, JB Wesley, K Sarkar, H Kimura, YV Liu, ... Circulation research 101 (12), 1310-1318, 2007 | 398 | 2007 |
| Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer S Dellapasqua, F Bertolini, V Bagnardi, E Campagnoli, E Scarano, ... Journal of Clinical Oncology 26 (30), 4899-4905, 2008 | 353 | 2008 |
| Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity Y Shaked, U Emmenegger, S Man, D Cervi, F Bertolini, Y Ben-David, ... Blood 106 (9), 3058-3061, 2005 | 322 | 2005 |
| Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy P Mancuso, M Colleoni, A Calleri, L Orlando, P Maisonneuve, G Pruneri, ... Blood 108 (2), 452-459, 2006 | 302 | 2006 |
| Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy R Munoz, S Man, Y Shaked, CR Lee, J Wong, G Francia, RS Kerbel Cancer research 66 (7), 3386-3391, 2006 | 276 | 2006 |
| Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study JLG Bender, PC Adamson, JM Reid, L Xu, S Baruchel, Y Shaked, ... Journal of clinical oncology 26 (3), 399-405, 2008 | 274 | 2008 |
| A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases GM Shaked, Y Shaked, Z Kariv-Inbal, M Halimi, I Avraham, R Gabizon Journal of Biological Chemistry 276 (34), 31479-31482, 2001 | 271 | 2001 |
| A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose … U Emmenegger, S Man, Y Shaked, G Francia, JW Wong, DJ Hicklin, ... Cancer research 64 (11), 3994-4000, 2004 | 207 | 2004 |
| The pro-tumorigenic host response to cancer therapies Y Shaked Nature Reviews Cancer 19 (12), 667-685, 2019 | 174 | 2019 |
| Targeted anti–vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia M Franco, S Man, L Chen, U Emmenegger, Y Shaked, AM Cheung, ... Cancer research 66 (7), 3639-3648, 2006 | 173 | 2006 |
| Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy Y Shaked, U Emmenegger, G Francia, L Chen, CR Lee, S Man, ... Cancer research 65 (16), 7045-7051, 2005 | 162 | 2005 |
| High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma R Buckstein, RS Kerbel, Y Shaked, R Nayar, C Foden, R Turner, CR Lee, ... Clinical cancer research 12 (17), 5190-5198, 2006 | 160 | 2006 |
| The multifaceted role of mesenchymal stem cells in cancer M Timaner, KK Tsai, Y Shaked Seminars in cancer biology 60, 225-237, 2020 | 159 | 2020 |
Francesco BertoliniDirector, Division of Laboratory Hematology-Oncology, European Institute of OncologyEmail được xác minh tại ieo.it